BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4054715)

  • 1. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
    Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
    Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
    Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
    Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
    [No Abstract]   [Full Text] [Related]  

  • 3. Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    J Surg Oncol; 1986 May; 32(1):43-5. PubMed ID: 3724190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of VP-16-213 in ovarian cancer.
    Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
    Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
    [No Abstract]   [Full Text] [Related]  

  • 5. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma.
    Dottino PR; Goodman HM; Kredentser D; Rosenberg M; Cohen CJ
    Gynecol Oncol; 1987 Jul; 27(3):350-6. PubMed ID: 3305186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin plus VP 16-213 in advanced ovarian carcinoma.
    Harnett PR; Bell DR; Hillcoat BL; Woods RL; Levi JA; Rome RM; Campbell JC; Tattersall MH
    Gynecol Oncol; 1988 Jun; 30(2):159-62. PubMed ID: 3371739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer.
    Chambers SK; Chambers JT; Kohorn EI; Schwartz PE
    Gynecol Oncol; 1987 Jun; 27(2):233-40. PubMed ID: 3570062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.
    Hansen F; Malthe I; Krog H
    Gynecol Oncol; 1990 Mar; 36(3):369-70. PubMed ID: 2318446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
    J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
    Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
    Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
    Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.
    Sierocki JS; Hilaris BS; Hopfan S; Martini N; Barton D; Golbey RB; Wittes RE
    Cancer Treat Rep; 1979; 63(9-10):1593-7. PubMed ID: 227598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
    Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
    Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.
    Goldhirsch A; Joss RA; Cavalli F; Sonntag RW; Brunner KW
    Med Pediatr Oncol; 1981; 9(3):205-8. PubMed ID: 6264280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
    Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
    Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer.
    Creagan ET; Eagan RT; Kvols LK
    Oncology; 1981; 38(5):260-1. PubMed ID: 7196561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
    Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.